Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies
Co-Diagnostics, Inc., a Utah company, has received the first Australian Patent for its new point-of-care testing platform, Co-Dx PCR Platform Technologies. The patent is the first granted for the platform and provides broad protection in Australia for the Company's proprietary system and methods used for nucleic acid detection and analysis. The claims specifically cover the design and operation of the CoDx PC Pro™ instrument and test cups, including its approach to performing high-quality polymerase chain reaction (PCR) testing outside of traditional laboratory environments. This patent represents a significant milestone in securing global protection for Co-DIagnostics' technology. The Co-DPP's platform is designed to deliver gold-standard PCR accuracy in a compact device suitable for decentralized testing environments.
نشرت : قبل 6 أشهر بواسطة في Finance
The Australian patent represents the first patent granted for the Company's new point-of-care testing platform
SALT LAKE CITY, Dec. 29, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-D... [5027 symbols]
المواضيع: Australia